The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab-based studies to understand this disease better. The list below highlights the ongoing trials being run by the IBC research program and clinic. Additional IBC clinical trials can be found at ClinicalTrials.gov.
If you would like more information about becoming involved with our clinical trials in general, you may email our program at firstname.lastname@example.org.
Protocol 2006-1072: Inflammatory breast cancer registry (Also open at select IBC Connect sites, through MD Anderson Cancer Network)
The IBC Registry is our master banking study, that allows us to collect blood and tissue samples to support the entire research program at MD Anderson and beyond. All patients with diagnosed or suspected IBC are eligible to be enrolled, regardless of treatment choices.
Currently Open Trials for Newly Diagnosed IBC
Protocol 2020-0715: Enhancing Immunotherapy by targeting the EGFR pathway in Inflammatory Breast Cancer: A phase II study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in combination with neoadjuvant chemotherapy (NAC) in patients with newly diagnosed triple negative inflammatory breast cancer (TN-IBC)
Study Manager: Angela Marx R.N., Tel: 713-792-5355, Email: email@example.com
Principal Investigator: Azadeh Nasrazadani M.D. Ph.D., Tel: 713-319-5955, Email: firstname.lastname@example.org
Currently Open Trials for Adjuvant Treatment
No current adjuvant trials are enrolling
Currently Open Local Therapy Trials
Currently Open Trials for Metastatic/Recurrent IBC
Protocol 2021-0077 - Phase Ib/II study of grapiprant (IK-007) and eribulin combination treatment for metastatic inflammatory breast cancer (mIBC)
Protocol 2022-0246 - Phase Ib/II Study of EPA-based EphA2 Targeted Therapy for Patients with Metastatic Triple-Negative Inflammatory Breast Cancer
Trials that allow IBC patients with logical targets:
Protocol 2016-1096 - A phase I study of OTS167 PO, a MELK inhibitor, to evaluate safety, tolerability and pharmacokinetics in patients with advanced breast cancer and dose-expansion study in patients with triple negative breast cancer
Study Managers: Vivian Chiv R.N., Tel: 713-792-4157, email@example.com and Danielle Alanis R.N., Tel: 713-563-1708, firstname.lastname@example.org
Principal Investigator: Senthil Damodaran M.D. Ph.D., Tel: 832-829-4307, email@example.com
Protocol 2021-0327 - A phase 1, first-in-human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors
Protocol 2020-0198 - Neratinib and Capmatinib combination (phase 1b/II) in metastatic breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-MET pathway activity as measured by CELsignia signaling analysis test